ERIS Lifescience

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406M01024
  • NSEID: ERIS
  • BSEID: 540596
INR
1,383.40
-1.9 (-0.14%)
BSENSE

Feb 02

BSE+NSE Vol: 42.72 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Acutaas Chemical
Emcure Pharma
Neuland Labs.
Sai Life
Astrazeneca Phar
ERIS Lifescience
Pfizer
Alembic Pharma
Jubilant Pharmo
Wockhardt
Piramal Pharma

Why is ERIS Lifesciences Ltd ?

1
Poor long term growth as Operating profit has grown by an annual rate 18.11% of over the last 5 years
2
With ROCE of 14.2, it has a Expensive valuation with a 4 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 11.92%, its profits have risen by 19.3% ; the PEG ratio of the company is 2.7
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ERIS Lifescience for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
ERIS Lifescience
11.61%
0.34
34.35%
Sensex
5.37%
0.47
11.36%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
21.37%
EBIT Growth (5y)
18.11%
EBIT to Interest (avg)
38.25
Debt to EBITDA (avg)
1.59
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.58
Tax Ratio
22.46%
Dividend Payout Ratio
0.28%
Pledged Shares
16.92%
Institutional Holding
27.17%
ROCE (avg)
17.25%
ROE (avg)
16.76%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
46
Industry P/E
32
Price to Book Value
6.21
EV to EBIT
27.94
EV to EBITDA
20.15
EV to Capital Employed
3.98
EV to Sales
7.17
PEG Ratio
2.69
Dividend Yield
0.52%
ROCE (Latest)
14.24%
ROE (Latest)
13.45%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
OPERATING CF(Y)

Highest at Rs 1,065.01 Cr

OPERATING PROFIT TO INTEREST(Q)

Highest at 5.82 times

NET SALES(Q)

Highest at Rs 792.41 cr

PBDIT(Q)

Highest at Rs 288.21 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 36.37%

PBT LESS OI(Q)

At Rs 169.86 cr has Grown at 36.37%

PAT(Q)

At Rs 120.19 cr has Grown at 31.2%

EPS(Q)

Highest at Rs 8.82

-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 7.31 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.63 times

Loading Valuation Snapshot...

Here's what is working for ERIS Lifescience

Operating Cash Flow - Annually
Highest at Rs 1,065.01 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 5.82 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales - Quarterly
Highest at Rs 792.41 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 288.21 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 36.37%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 169.86 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 169.86 cr has Grown at 36.37%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 120.19 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 120.19 cr has Grown at 31.2%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 8.82
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for ERIS Lifescience

Inventory Turnover Ratio- Half Yearly
Lowest at 7.31 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio- Half Yearly
Lowest at 4.63 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio